ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1048

Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study

R Westhovens1, Rieke Alten2, Dace Pavlova3, Favio Enríquez-Sosa4, Minodora Mazur5, Maria Greenwald6, Annegret Van der Aa7, Frédéric Vanhoutte7, Chantal Tasset7 and Pille Harrison7, 1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, 2Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3LTD M & M Centrs, Carnikava, Latvia, 4CLINSTILE, S.A. DE C.V, Mexico, Mexico, 5IMSP Institul de Cardiologie, Chisinau, Moldova, 6Desert Medical Advances, Palm Desert, CA, 7Galapagos NV, Mechelen, Belgium

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: clinical trials, Effective, Janus kinase (JAK), rheumatoid arthritis (RA) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy II: Small Molecular Targeted Therapies

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid arthritis (RA) in 4-week phase 2A studies with an acceptable safety profile. The purpose of this study was to evaluate efficacy and safety of different doses and dose regimens of filgotinib versus placebo (PBO) in patients with active RA with inadequate response to MTX.

Methods: Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blinded manner to receive either PBO or one of three doses of filgotinib (50mg, 100mg or 200mg) as  once (qd) or twice daily (bid) regimen for 24 weeks (DARWIN 1 study). The primary endpoint was the proportion of patients achieving ACR 20 response at week 12.  Reported data are from the planned 12 weeks analysis.

Results: Of 594 randomized and treated patients, 76-86% were females with a mean age across groups of 52-55 years, mean duration of RA of 7-10 years and DAS28(CRP) at baseline ranging from 6.0-6.2. Patients were well distributed across different geographical regions. At week 12, a statistically significant higher ACR20 response versus PBO was observed with 200mg daily dose. For other key efficacy endpoints (ACR50, ACR-N, DAS28(CRP), CDAI, SDAI) all doses showed significant differences versus PBO. No statistically significant difference between qd and bid regimens was seen. By week 12, 24-50% of patients on filgotinib achieved low disease activity (DAS28(CRP)≤ 3.2) in a dose dependent manner, compared to 14% on PBO. Onset of efficacy was rapid for ACR-N, DAS28(CRP) and SDAI with significant differences seen from week 1 onwards at 200mg daily dose.

Table 1. Summary of the ACR/DAS28(CRP)/CDAI responses after 12 weeks treatment:

 

 

Once-daily   dosing

Twice-daily   dosing

 

Placebo

n=86

50mg

n=82

100mg

n=85

200mg

n=86

25mg

n=86

50mg

n=85

100mg

n=84

ACR20, NRI1, %

45

56

62

69*

57

59

80***

ACR50, NRI, %

15

32*

39**

43***

28*

34*

55***

ACR70, NRI, %

8

16

20

24*

14

19

31**

ACR-N, LOCF2, %

23

34*

38**

42***

33*

36*

51***

DAS28(CRP), mean change from BL3,   LOCF

-1.2

-1.8*

-2.2***

-2.5***

-1.9**

-2.1***

-2.8***

CDAI4, mean change   from BL, LOCF

-17

-20

-24**

-26***

-21*

-23**

-29***

* p< 0.05 vs. placebo; ** p<0.01 vs. placebo; *** p<0.001 vs. placebo;  ACR scores based on ITT analysis. 1Non-responder imputation. 2 Last observation carried forward.3 Baseline.  4Clinical Disease Activity Index.

Conclusion: Over 12 weeks, filgotinib in combination with MTX demonstrated consistent efficacy on signs and symptoms of active RA with a rapid onset of action. The safety profile was overall favorable and consistent with previous studies conducted in RA with filgotinib.


Disclosure: R. Westhovens, Roche Pharmaceuticals, 2,Bristol-Myers Squibb, 8,Janssen, Galapagos, 5; R. Alten, None; D. Pavlova, None; F. Enríquez-Sosa, None; M. Mazur, None; M. Greenwald, None; A. Van der Aa, Galapagos, 3; F. Vanhoutte, Galapagos NV, 3; C. Tasset, Galapagos, 3; P. Harrison, Galapagos, 3.

To cite this abstract in AMA style:

Westhovens R, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/filgotinib-glpg0634-an-oral-jak1-selective-inhibitor-is-effective-in-combination-with-methotrexate-in-patients-with-active-rheumatoid-arthritis-results-from-a-phase-2b-dose-ranging-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/filgotinib-glpg0634-an-oral-jak1-selective-inhibitor-is-effective-in-combination-with-methotrexate-in-patients-with-active-rheumatoid-arthritis-results-from-a-phase-2b-dose-ranging-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology